Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability

(2019) Ena Ladi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular Approaches to Treating Pediatric Leukemias

(2019) Michaela Kuhlen et al.   Frontiers in Pediatrics

Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence

(2018) Mara Gavazzoni et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

(2018) Henry W. B. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma

(2017) Gilbert J Rahme et al.   NEURO-ONCOLOGY

Proteasome inhibitor-induced gastrointestinal toxicity

(2017) Romany L. Stansborough et al.   Current Opinion in Supportive and Palliative Care

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches

(2017) Amanda C. Winters et al.   Frontiers in Pediatrics

Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines

(2017) Kazuya Takahashi et al.   PLoS One

Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma

(2016) Rimda Wanchoo et al.   Clinical Journal of the American Society of Nephrology

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

(2016) Denise Niewerth et al.   Journal of Hematology & Oncology

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program

(2016) L Jones et al.   LEUKEMIA

A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities

(2015) Gerjan de Bruin et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

The novel  2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

(2015) M. Kraus et al.   HAEMATOLOGICA

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

(2015) Lukas D. Wartman et al.   LEUKEMIA & LYMPHOMA

The novel  2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

(2015) M. Kraus et al.   HAEMATOLOGICA

Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4

(2014) Han Liu et al.   CANCER CELL

Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits and p97

(2014) Zhe Sha et al.   CURRENT BIOLOGY

Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes

(2014) Gerjan de Bruin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bortezomib treatment causes long-term testicular dysfunction in young male mice

(2014) Mi Hou et al.   Molecular Cancer

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites

(2013) Paul P. Geurink et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib

(2013) Tamer B. Shabaneh et al.   PLoS One

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

(2012) Y. H. Messinger et al.   BLOOD

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

Bortezomib Is Cytotoxic to the Human Growth Plate and Permanently Impairs Bone Growth in Young Mice

(2012) Emma Eriksson et al.   PLoS One

Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib

(2011) Anne C. Mirabella et al.   CHEMISTRY & BIOLOGY

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Mice completely lacking immunoproteasomes show major changes in antigen presentation

(2011) Eleanor Z Kincaid et al.   NATURE IMMUNOLOGY

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proteome of platelets in patients with coronary artery disease

(2010) Cristina Banfi et al.   EXPERIMENTAL HEMATOLOGY

Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome

(2010) M. Basler et al.   JOURNAL OF IMMUNOLOGY

Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells

(2010) Senthil K. Radhakrishnan et al.   MOLECULAR CELL

Proteasomal Degradation Is Transcriptionally Controlled by TCF11 via an ERAD-Dependent Feedback Loop

(2010) Janos Steffen et al.   MOLECULAR CELL

A panel of subunit-selective activity-based proteasome probes

(2010) Martijn Verdoes et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules

(2010) B. Guillaume et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites

(2009) Matthew Britton et al.   CHEMISTRY & BIOLOGY

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

(2008) Deborah J. Kuhn et al.   BLOOD